
Bristol-Myers (BMY) Stock Forecast & Price Target
Bristol-Myers (BMY) Analyst Ratings
Bulls say
Bristol-Myers Squibb is expected to have a strong quarter driven by growth products such as Opdivo and Qvantig, as well as continued growth in Eliquis. The team is confident in the company's 10-15% growth target for Eliquis for the year, with a focus on cost considerations. With upcoming clinical readouts and potential label expansions, Bristol-Myers Squibb has the opportunity for multiple expansion and is a buy according to analysts, with a target price of $72.
Bears say
Bristol-Myers Squibb is facing downside risks due to potential competition in its key therapeutic areas, clinical failures in their pipeline, and potential regulatory delays. With 70% of total sales coming from the US, the company is highly exposed to any changes in the US market, posing additional macro/policy-related risks. Despite its strong position in the immuno-oncology market, these risks could lead to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.
Bristol-Myers (BMY) Analyst Forecast & Price Prediction
Start investing in Bristol-Myers (BMY)
Order type
Buy in
Order amount
Est. shares
0 shares